Part D Off-Label Prescription Parity Act

-S. 1273, National MS and Parkinson's Disease Registries Act, support all provisions. -H.R. 1362, National Neurological Diseases Surveillance System Act, support all provisions. -H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -H.R. 6208, Adult Day Achievement Center Enhancement Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S. 677 - Oppose means-tested Medicare Part D premiums Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Fibromyalgia patients access to medicines Oppose Physician-Owned Hospital reimbursement ban Support "six protected classes" in Medicare Part D Support reduction or elimination of the "two-year wait" for Medicare for the disabled Support Medicare Part D "off-label" drug rules similar to those relating to Medicare Part B Oppose off-label drug mandates by insurance companies that replace approved medications Oppose specialty tiers, therapeutic substitution, step therapy, dose restrictions and/or quantity limits that supplant first line treatments and physician orders for cost purposes Oppose using Medicare cuts to pay for Health Care Reform in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support H.R. 5732, the Part D Off-Label Prescription Parity Act. Support Medicare reimbursement for Provenge to treat prostate cancer. Support the Medicare Access for Patients Rx (MAPRx) coalition's comments to United States Pharmacopeia regarding draft Model Guidelines (Version 5.0) for the Medicare Part D Prescription Drug Program.

Client expense: Not reported · Firm income: $13,310

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 1362, "The National Neurological Diseases Surveillance System Act," all sections; S. 1273, "The National MS and Parkinson's Disease Registries Act," all sections; "Supplemental Appropriations Act, 2010," section relating to the limitation on use of funds available to the Department of Veterans Affairs; H.R.5732, "Part D Off-Label Prescription Parity Act," all sections; "Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2011," all sections relating to the National Institutes of Health (NIH), Cures Acceleration Network at NIH, and National Institute of Environmental Health Sciences; "Department of Defense Appropriations Act, 2011," section related to the Neurotoxin Exposure Treatment Parkinson's Research (NETPR) program; "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011," all sections regarding the FDA and regulatory science; H.R 4808, "Stem Cell Research Advancement Act of 2009," all sections; S. 3766, "The Stem Cell Research Advancement Act of 2010," all sections; legislation and regulation relating to the extension of the Medicare Part B therapy cap exceptions process and Multiple Procedure Payment Reduction Policy for rehabilitation services; HR 1347, "The Concussion Treatment and Care Tools Act of 2009," all sections; and Fiscal Year 2012 funding for the NIH Institute on Aging.

Client expense: $10,000 · Firm income: Not reported

S. 677 - Oppose means-tested Medicare Part D premiums Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Fibromyalgia patients access to medicines Oppose Physician-Owned Hospital reimbursement ban Support "six protected classes" in Medicare Part D Support reduction or elimination of the "two-year wait" for Medicare for the disabled Support Medicare Part D "off-label" drug rules similar to those relating to Medicare Part B Oppose off-label drug mandates by insurance companies that replace approved medications Oppose specialty tiers, therapeutic substitution, step therapy, dose restrictions and/or quantity limits that supplant first line treatments and physician orders for cost purposes Oppose using Medicare cuts to pay for Health Care Reform in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support H.R. 5732, the Part D Off-Label Prescription Parity Act.

Client expense: $176,190 · Firm income: Not reported

-H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions. -HR 1586, Education Jobs and Medicaid Assistance Act, support extension of federal Medicaid assistance to states.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

-S. 1273, National MS and Parkinson's Disease Registries Act, support all provisions. -H.R. 1362, National Neurological Diseases Surveillance System Act, support all provisions. -H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -HR 1586, Education Jobs and Medicaid Assistance Act, support extension of federal Medicaid assistance to states. -H.R. 6208, Adult Day Achievement Center Enhancement Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S. 677 - Oppose means-tested Medicare Part D premiums Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Fibromyalgia patients access to medicines Oppose Physician-Owned Hospital reimbursement ban Support "six protected classes" in Medicare Part D Support reduction or elimination of the "two-year wait" for Medicare for the disabled Support Medicare Part D "off-label" drug rules similar to those relating to Medicare Part B Oppose off-label drug mandates by insurance companies that replace approved medications Oppose specialty tiers, therapeutic substitution, step therapy, dose restrictions and/or quantity limits that supplant first line treatments and physician orders for cost purposes Oppose using Medicare cuts to pay for Health Care Reform in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support H.R. 5732, the Part D Off-Label Prescription Parity Act.

Client expense: Not reported · Firm income: $13,695